Skip to main content

Table 19 (a) Anti HIV activity of synthesized compounds. (b) Cytotoxicity and antiviral activity of titled compounds in Vero cell cultures. (c) Cytotoxicity and antiviral activity of titled compounds in HEL cell cultures [47]

From: Therapeutic potential of oxadiazole or furadiazole containing compounds

Panel (a)
Compound HIV I (μg/ml) SI HIV II (μg/ml)) SI
IC50 CC50 IC50 CC50
35a  > 50  = 50  < 1  > 57  = 57  < 1
35b  > 65  = 65  < 1  > 60  = 60  < 1
35c  > 125  > 125 X1  > 125  > 125 X1
35f  > 125  > 125 X1  > 38  > 125  > 3
35 g  > 125  > 125 X1  > 125  > 125 X1
35 h  > 125  > 125 X1  > 125  > 125 X1
35i  > 125  > 125 X1  > 125  > 125 X1
35j  > 125  > 125 X1  > 125  > 125 X1
Nevirapine(μM)  > 0.25  > 200  > 800
DDI (μM)  > 5.37  > 529  > 98 2.71  > 529  > 195
Panel (b)
Compound Minimum cytotocic concentrationa (μg/mL) EC50b (μg/mL)
Para-influenza-3 virus Retrovirus Sindbis virus Coxasacide B4 virus Punta Toro virus
35a 20  > 20  > 20  > 20  > 20  > 20
35b 100  > 20  > 20  > 20  > 20  > 20
35c 100  > 20  > 20  > 20  > 20  > 20
35f  > 100  > 100  > 100  > 100  > 100  > 100
35 g  > 100  > 100  > 100  > 100  > 100  > 100
35 h  > 100  > 100  > 100  > 100  > 100  > 100
35i  > 100  > 100  > 100  > 100  > 100  > 100
35j  > 100  > 100  > 100  > 100  > 100  > 100
Ribavirin (μM)  > 250 146 250  > 250  > 250 146
Panel (c)
Compound Minimum cytotocic concentrationa (μg/mL) EC50b (μg/mL)
Herpes simplex virus-1 Herpes simplex virus-2 Vaccinia virus Vesicular stomatitis virus
35a  > 100 50 100 45  > 100
35b 100  > 20  > 20  > 20  > 20
35c  > 100  > 100  > 100  > 100  > 100
35f  > 100  > 100  > 100  > 100  > 100
35g  > 100  > 100  > 100  > 100  > 100
35h  > 100  > 100  > 100  > 100  > 100
35i  > 100  > 100  > 100  > 100  > 100
35j  > 100  > 100  > 100  > 100  > 100
Brivudin (μM)  > 250 0.04 50 2 250
Cidofovir (μM)  > 250 1 1 2  > 250
Ganciclovir (μM)  > 100 0.02 0.07  > 100  > 100
  1. aConcentration required to cause a microscopically detectable alteration of normal cell morphology, bConcentration required to reduce virus-induced cytopathogenicity by 50%